BERN, Switzerland, April 21, 2011 /PRNewswire/ -- CSL Behring announced today that the European Commission has granted marketing authorization for Hizentra(R) (Human Normal Immunoglobulin), 20 percent solution for subcutaneous injection, for treating patients diagnosed with primary immunodeficiency (PI) as well as secondary immunodeficiencies. This authorization is valid for all 29 European/European Economic Area member states.
CSL Behring is a subsidiary of CSL Limited . Hizentra is currently marketed in the United States. It received U.S. Food and Drug Administration approval in March 2010.